Compare Ascendis Pharma A/S (ASND) vs Corsair Gaming Inc (CRSR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Corsair Gaming Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Corsair Gaming Inc trades at $9.31 (market cap $1.03B). The key difference: Ascendis Pharma A/S is far larger — about 17.2× Corsair Gaming Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Corsair Gaming Inc nearer its low. Which is the better fit depends on your goals.
| ASND | CRSR | |
|---|---|---|
Market Cap | $17.74B | $1.03B |
Sector | Health | Technology |
52-Week High | $277.18 | $12.14 |
52-Week Low | $163.32 | $4.58 |
Enterprise Value | $18.11B | $1.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Corsair Gaming (CRSR) trades at $9.66, up 1.15% with a bullish technical outlook. The stock shows mixed fundamentals with a high P/E ratio of 107.33 but attractive P/S of 0.71, while recent earnings beats and new AI product launches drive optimism. Revenue remains stable around $1.5B, though profitability is inconsistent with a net margin of just 0.49%.
Corsair presents a speculative opportunity with strong product innovation but faces execution risks. Analyst consensus is cautious with a $9 price target below current levels. The company's pivot to AI hardware and gaming partnerships offers growth potential, but thin margins and competitive pressures require careful monitoring for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →
